FEBRUARY 11 (hours are in Italy Local Time)

3.45 p.m. Opening remarks

4.00 p.m. Melcangi R.C. (Italy): Allopregnanolone: an overview on its synthesis and effects

4.30 p.m. Lambert J.J. (UK): Realising the therapeutic potential of neuroactive steroid modulators of the GABAa receptor

5.00 p.m. Gunduz-Bruce H. (USA): Clinical trials in postpartum depression with brexanolone and zuranolone

5.30 p.m. Bortolato M. (USA): The other side of the coin: neuropsychiatric side effects of allopregnanolone

FEBRUARY 12

4.00 p.m. Backstrom T. (Sweden): Allopregnanolone and Isoallopregnanolone, GABA-A receptor modulators with different effects useful in clinical conditions

4.30 p.m. Rasmusson A.M. (USA): A Role for Deficits in GABAergic Neurosteroids and Their Metabolites with NMDA-Receptor Antagonist Activity in the Pathophysiology of PTSD

5.00 p.m. Mennerick S (USA): Allopregnanolone: GABA-A receptors and beyond.

5.30 p.m. Reddy D.S. (USA): Cell-Specific and Phosphorylation-Dependent Actions of Brexanolone (Allopregnanolone) Analogs in Epilepsy and Brain Disorders